Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04765384 · ClinicalTrials.gov registry record · Phase 2
A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)
A Phase 2 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT04765384 is a Phase 2 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 51 participants.
The verdict
NCT04765384, a Phase 2 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immune response in peripheral blood of adult participants to Ad26.COV2.S administered IM as a 1-dose schedule during the second and/or third trimester of pregnancy, 28 days after vaccination.
Interventions
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2023-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04765384
The ClinicalTrials.gov registry entry for NCT04765384 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad26.COV2.S is the first listed.
NCT04765384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04765384 about?
NCT04765384 is a clinical study titled "A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)". The purpose of this study is to assess the safety and reactogenicity of Ad26.COV2.S administered intramuscularly (IM) as a 1-dose schedule at the standard dose level in adult participants during the second and/or third trimester of pregnancy and (potentially) post-partum; to assess the humoral immun...
What is the current status of trial NCT04765384?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2021-08-27. Estimated completion is 2023-11-24.
What interventions are being tested in trial NCT04765384?
The interventions under investigation include: Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04765384?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.